Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.36 |
| ▸ | BUB1 | O43683 | 2/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15057625 | 0.91 | PLA2G4A (0.45) | PLA2G4ASLC16A3SLC16A1KMO | |
| SCHEMBL15057571 | 0.86 | NPBWR1 (0.45) | SLC16A3SLC16A1NPBWR1MAOAMAOB | |
| SCHEMBL15076172 | 0.84 | NLRP3 (0.44) | KMO | |
| SCHEMBL15057111 | 0.83 | MAOA (0.44) | PLA2G4ASLC16A3SLC16A1NPBWR1ESR2 | |
| SCHEMBL15057991 | 0.83 | KDM4E (0.39) | PLA2G4AMAOAMAOBLMNAMAPT | |
| SCHEMBL15058057 | 0.81 | HTR2A (0.41) | SLC16A3SLC16A1MAOAMAOBKMO | |
| SCHEMBL15058170 | 0.76 | NLRP3 (0.44) | MAOAMAOB | |
| SCHEMBL20629002 | 0.76 | CHRM1 (0.35) | PLA2G4AKMOLMNA | |
| SCHEMBL15057888 | 0.74 | KMO (0.45) | PLA2G4AKMO | |
| SCHEMBL15057792 | 0.74 | XDH (0.40) | PLA2G4AMAOAMAOBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3424904-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | Allergan, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2794561-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2794561-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PLA2G4A 181/4885SLC16A3 3894/4885SLC16A1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.